Maxim Group
http://www.maximgrp.com/Maxim Group is a financial services firm that provides investment banking, asset management, research, and sales & trading to a diverse range of corporate clients, institutional investors and high net worth individuals.
The firm’s research division uses fundamental research and a “bottom up” approach to making investment recommendations. Maxim’s research analysts focus on under-covered, small- to mid-cap names in a variety of sectors including healthcare, technology, retail and others.
View Older Stories View More Recent Stories
-
Auris Medical Announces Pricing of $10 Million Public Offering
-
Celsion (CLSN) Sells $5M in Common stock at $0.23/Share w/Warrants
-
Celsion Corporation Announces $5.0 Million Public Offering
-
Maxim Group Downgrades Cynosure (CYNO) to Hold
-
Maxim Group Downgrades Cynosure (CYNO) to Hold
-
New Age Beverages Corporation Prices $15,000,000 Public Offering And Listing on the NASDAQ Capital Market
-
PennantPark Floating Rate Capital (PFLT) to Sell 5M Shares at $14.08
-
PennantPark Floating Rate Capital Ltd. Prices Public Offering
-
Maxim Group Reiterates Buy Rating and $4 PT on ContraVir Pharmaceuticals (CTRV); HBV Data at Upcoming Conference
-
Maxim Group Downgrades ZELTIQ Aesthetics (ZLTQ) to Hold
-
Teva Pharma (TEVA) PT Lowered to $40 at Maxim Group
-
Ritter Pharmaceuticals (RTTR) PT Raised to $5 at Maxim Group
-
Maxim Group Downgrades Pluristem Therapeutics (PSTI) to Hold
-
Provectus Biopharmaceuticals, Inc. Announces Extension of Rights Offering
-
Sonoma Pharmaceuticals (SNOA) PT Raised to $9 at Maxim Group on Break Even Push
-
Interpace Diagnostics Announces Closing of $3.9 Million Public Offering
-
Maxim Group Downgrades First Community Financial (FCFP) to Hold
-
Interpace Diagnostics (IDXG) Prices 1.2M Shares at $3
-
Interpace Diagnostics Announces Pricing of Public Offering to Raise $3.6 Million
-
Interpace Diagnostics (IDXG) Plans Public Offering of Common Stock
-
Interpace Diagnostics Announces Proposed Public Offering of Common Stock
-
Maxim Group Downgrades Galena Biopharma (GALE) to Hold
-
Athersys Announces Closing of Public Offering of Common Stock
-
Provectus Biopharmaceuticals, Inc. Announces Commencement Of Rights Offering To Existing Stockholders And Holders Of Certain Warrants
-
Cerecor (CERC) Reports ATM Equity Offering Program
-
Cerecor Announces At-the-Market Equity Offering Program
-
Athersys (ATHX) Prices 19.8M Shares at $1.01
-
Athersys Announces Pricing of Public Offering of Common Stock
-
KeyW Holding (KEYW) 8.5M Share Offering Prices at $10.50
-
KeyW Announces Pricing of Public Offering of Common Stock
-
Maxim Group Starts Mateon Therapeutics (MATN) at Buy
-
KeyW (KEYW) Announces 8.5M Public Offering of Common Stock
-
KeyW Announces Public Offering of Common Stock
-
Pre-Open Stock Movers 01/26: (AVGR) (CHTR) (MGI) Higher; (MAT) (MCK) (FFIV) Lower (more...)
-
Maxim Group Upgrades Capnia (CAPN) to Buy, $5 PT
-
Adamis Pharmaceuticals (ADMP): EpiPen Wars Emerge - Maxim
-
Maxim Group Upgrades ADMA Biologics (ADMA) to Buy
-
CytoSorbents (CTSO) PT Raised to $10 at Maxim Group
-
Milestone Scientific Inc. Announces Partial Exercise of Over-Allotment Option
-
Interpace Diagnostics (IDXG) Enters $4M Common Stock Securities Purchase Agreement
-
Interpace Diagnostics Announces $4.0 Million Registered Direct Offering of Common Stock
-
Interpace Diagnostics (IDXG) to Offer 855K Common Shares and Warrants
-
Amedica (AMDA) Prices $4.5M Offering of Common Stock and Warrants
-
Amedica Announces Pricing of Public Offering to Raise $4.5 Million
-
Maxim Group Starts BioLife Solutions (BLFS) at Buy, $3 PT
-
Amedica (AMDA) Plans Offering of Common Stock and Warrants
-
Amedica Announces Proposed Public Offering of Common Stock and Warrants
-
Medley Management Inc. Announces Closing of $34.5 Million Medley LLC Public Offering of 7.25% Notes Due 2024
-
PlacementTracker Publishes 2016 Private Placement Market League Tables
-
Kite Pharma (KITE): China JV Could Bring $140 In Royalties - Maxim

